Literature DB >> 3090930

Free kappa light chains in multiple sclerosis spinal fluid.

R A Rudick, A Pallant, J M Bidlack, R M Herndon.   

Abstract

Based on prior reports of free light chains of immunoglobulin G (IgG) in the cerebrospinal fluid (CSF) of patients with multiple sclerosis (MS), we quantitated free kappa and lambda chains and whole IgG concentrations using sensitive and specific radioimmunoassays (RIAs). The RIA for free kappa chains had a sensitivity of 0.25 micrograms/ml and was capable of specifically measuring free kappa chains in whole CSF or serum even in the presence of a 4-log excess of whole IgG. By RIA, free kappa chains were detected in CSF samples from 33 (84%) of 39 MS patients but in only 1 (2.4%) of 42 controls. The control patients included 10 with noninfectious inflammatory diseases and 9 with central nervous system infections. The concentration of free kappa chains in the CSF of the MS patients was 1.40 +/- 1.21 micrograms/ml. Free kappa chains were concentrated in the CSF 71- to 120-fold relative to reference proteins. In contrast, increased levels of free lambda chains or of whole IgG were nonspecific; abnormalities were seen in controls with infections or inflammatory diseases as often as in MS patients. These studies suggest that the measurement of free kappa light chains may have important diagnostic usefulness, since the specificity of the finding for MS appears to be high.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3090930     DOI: 10.1002/ana.410200111

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  7 in total

1.  Quantification of immunoglobulin free light chains in cerebrospinal fluid by nephelometry.

Authors:  Sophie Desplat-Jégo; Lionel Feuillet; Jean Pelletier; Dominique Bernard; André Ali Chérif; José Boucraut
Journal:  J Clin Immunol       Date:  2005-07       Impact factor: 8.317

2.  Elevated levels of kappa free light chains in CSF support the diagnosis of multiple sclerosis.

Authors:  Stefan Presslauer; Dejan Milosavljevic; Thomas Brücke; Peter Bayer; Wolfgang Hübl; Walter Hübl
Journal:  J Neurol       Date:  2008-07-17       Impact factor: 4.849

3.  Immunoglobulin M in the cerebrospinal fluid: an indicator of recent immunological stimulation.

Authors:  M K Sharief; E J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-08       Impact factor: 10.154

4.  Cyclosporin A curtails the progression of free light chain synthesis in the CSF of patients with multiple sclerosis.

Authors:  B N McLean; P Rudge; E J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-04       Impact factor: 10.154

5.  Assessment of Intrathecal Free Light Chain Synthesis: Comparison of Different Quantitative Methods with the Detection of Oligoclonal Free Light Chains by Isoelectric Focusing and Affinity-Mediated Immunoblotting.

Authors:  David Zeman; Pavlína Kušnierová; Zdeněk Švagera; František Všianský; Monika Byrtusová; Pavel Hradílek; Barbora Kurková; Olga Zapletalová; Vladimír Bartoš
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240

6.  Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study.

Authors:  C E Leurs; Ham Twaalfhoven; B I Lissenberg-Witte; V van Pesch; I Dujmovic; J Drulovic; M Castellazzi; T Bellini; M Pugliatti; J Kuhle; L M Villar; J C Alvarez-Cermeño; R Alvarez-Lafuente; H Hegen; F Deisenhammer; L M Walchhofer; E Thouvenot; M Comabella; X Montalban; L Vécsei; C Rajda; D Galimberti; E Scarpini; A Altintas; K Rejdak; J L Frederiksen; G Pihl-Jensen; Peh Jensen; M Khalil; M M Voortman; F Fazekas; A Saiz; D La Puma; M Vercammen; L Vanopdenbosch; Bmj Uitdehaag; J Killestein; C Bridel; C Teunissen
Journal:  Mult Scler       Date:  2019-05-08       Impact factor: 6.312

Review 7.  The Increasing Role of Kappa Free Light Chains in the Diagnosis of Multiple Sclerosis.

Authors:  Franz Felix Konen; Philipp Schwenkenbecher; Konstantin Fritz Jendretzky; Stefan Gingele; Kurt-Wolfram Sühs; Hayrettin Tumani; Marie Süße; Thomas Skripuletz
Journal:  Cells       Date:  2021-11-06       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.